Data from the phase 3 RADICALS-RT, RAVES, and GETUG-AFU 17 trials and the ARTISTIC meta-analysis suggest that observation with early salvage radiotherapy should be the standard of care for men undergoing radical prostatectomy for localized or locally advanced prostate cancer.
Dual pathway inhibition with the AKT inhibitor ipatasertib plus the androgen receptor inhibitor abiraterone may benefit certain patients with treatment-naïve, metastatic castration-resistant prostate cancer, phase 3 IPATential150 trial data suggest.
Men with metastatic castration-resistant prostate cancer who receive ipilimumab after radiotherapy to bone metastases have a significantly better long-term survival rate than those who receive placebo, study findings indicate.
Phase 2 TRITON2 study data suggest that men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 mutation may benefit from treatment with the PARP inhibitor rucaparib.
Starting radiotherapy up to 6 months after androgen deprivation therapy may be feasible for men with intermediate- and high-risk localized prostate cancer, say US researchers who found that overall survival was comparable regardless of the timing of radiotherapy initiation.
The use of chemohormonal therapy before radical prostatectomy does not significantly improve 3-year biochemical recurrence-free survival in men with localized, high-risk prostate cancer, phase 3 trial findings suggest.
Two modelling studies published in The Lancet Oncology show the impact cancer diagnostic delays due to COVID-19 could have in England, with some scenarios suggesting over a 1000 people could die unnecessarily.
The HSD3B1 CC pathogenic variant does not add prognostic information to standard clinical variables for men receiving abiraterone or enzalutamide for metastatic castration-resistant prostate cancer, study findings indicate.
A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.
Adding an androgen receptor inhibitor to androgen deprivation therapy significantly improves the overall survival of men with nonmetastatic castration-resistant prostate cancer, according to results from three trials.
Positron-emission tomography using the novel prostate-specific membrane antigen targeted 18F-DCFPyL tracer shows “excellent diagnostic performance” in men with biochemically recurrent prostate cancer, researchers report.
Men with advanced prostate cancer who receive the gonadotropin-releasing hormone antagonist relugolix are more likely to have sustained suppression of testosterone than those treated with leuprolide acetate, HERO trial data show.
Adding androgen deprivation therapy to external beam radiotherapy may result in better survival than adding a brachytherapy boost in men with intermediate- and high-risk prostate cancer, network meta-analysis data suggest.
Men with metastatic castration-resistant prostate cancer (mCRPC) who carry the CC genotype of the HSD3B1 c.1245A>C variant have worse responses to first-line abiraterone and enzalutamide than those with an AA or AC genotype, research shows.